September 12, 2011
Pfizer’s novel, oral ALK (anaplastic lymphoma kinase) inhibitor crizotinib, which was submitted for approval in Japan and the US in May, was approved by the US FDA on August 26. The drug was designated for priority review with approval expected...read more